The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Provided herein are luminescent compounds, compositions including the same, and use and synthesis thereof.

Provided herein are luminescent compounds, compositions including the same, and use and synthesis thereof.

The present invention relates to an. organic semiconductive layer which is an electron transport layer and/or an electron injection layer and/or an n-type charge generation layer, the organic semiconductive layer comprising at least one compound of formula (1) wherein R.sup.1 and R.sup.2 are each independently selected from C.sub.1 to C.sub.16 alkyl; Ar.sup.1 is selected from C.sub.6 to C.sub.14 arylene or C.sub.3 to C.sub.12 heteroarylene; Ar.sup.2 is independently selected from C.sub.14 to C.sub.40 arylene or C.sub.8 to C.sub.40 heteroarylene; R.sup.3 is independently selected from H, C.sub.1 to C.sub.12 alkyl or C.sub.10 to C.sub.20 aryl; wherein each of Ar.sup.1, Ar.sup.2 and R.sup.3 may each independently be unsubstituted or substituted with at least one C.sub.1 to C.sub.12 alky group; n is 0 or 1; and m is 1 in case of n=0; and m is 1 or 2 in case of n=1, phosphine oxide compounds comprised therein and to organic electroluminescent devices comprising such layers and compounds. ##STR00001##

New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.

New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

According to a nonaqueous electrolytic solution containing: (I) at least one selected from the group consisting of a compound represented by General Formula (1) described in the specification (for example, a compound represented by the following Formula (1a)) and a compound represented by General Formula (2) (for example, a compound represented by the following Formula (2a)); (II) a solute; and (III) a nonaqueous organic solvent, a nonaqueous electrolytic solution and a nonaqueous electrolytic solution battery having a low initial resistance value, and a compound that can be suitably used in the above nonaqueous electrolytic solution can be provided;

##STR00001##